Canary Bio Begins Preclinical Development of Oregovomab for Endometriosis Treatment with Asan Medical Center

Canary Bio announced that it has started preclinical development of oregovomab, which is being developed as an ovarian cancer treatment, as a treatment for endometriosis in collaboration with Professor Yongman Kim's team at Asan Medical Center.

Endometriosis is a condition that occurs in 10-15% of women of reproductive age, where endometrial tissue attaches to and proliferates on tissues other than the uterus, such as uterine ligaments, bladder, and colon, causing inflammation. High concentrations of CA125 are often detected in the blood of patients with endometriosis. Professor Yongman Kim's team will evaluate the efficacy of oregovomab targeting CA125 for endometriosis using an endometriosis mouse model.

According to the World Health Organization, endometriosis affects approximately 190 million women worldwide, about 10% of women of reproductive age. In South Korea, analysis of endometriosis treatment data (2016?2020) released by the National Health Insurance Service shows that the number of patients treated for endometriosis in 2020 was 155,183, an increase of 50,494 over five years. The number is increasing at an average annual rate of 10.3%.

CEO Hanahik said, "Treatment for endometriosis generally involves surgical treatment and drug therapy that regulates estrogen production, but the recurrence rate of endometriosis patients within five years after surgery is about 40-50%, so the development of new treatment options is urgently needed."

This content was produced with the assistance of AI translation services.